BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Journal article published in 2020 by
Gautam Borthakur,
Yishai Ofran,
Martin S. Tallman,
James Foran 
,
Geoffrey L. Uy,
John F. DiPersio,
Margaret M. Showel,
Avichai Shimoni ,
Arnon Nagler,
Jacob M. Rowe,
Jessica K. Altman,
Michal Abraham,
Amnon Peled,
Stephen Shaw,
Osnat Bohana‐Kashtan
and other authors.
,
Geoffrey L. Uy,
John F. DiPersio,
Margaret M. Showel,
Avichai Shimoni ,
Arnon Nagler,
Jacob M. Rowe,
Jessica K. Altman,
Michal Abraham,
Amnon Peled,
Stephen Shaw,
Osnat Bohana‐Kashtan
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 